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Abstract 
Background: Rapid molecular diagnostic tests to investigate the microbial aetiology of pneumonias may improve 
treatment and antimicrobial stewardship in intensive care units (ICUs). Clinicians’ endorsement and uptake of these 
tests is crucial to maximise engagement; however, adoption may be impeded if users harbour unaddressed concerns 
or if device usage is incompatible with local practice. Accordingly, we strove to identify ICU clinicians’ beliefs about 
molecular diagnostic tests for pneumonias before implementation at the point-of-care.
Methods: We conducted semi-structured interviews with 35 critical care doctors working in four ICUs in the United 
Kingdom. A clinical vignette depicting a fictitious patient with signs of pneumonia was used to explore clinicians’ 
beliefs about the importance of molecular diagnostics and their concerns. Data were analysed thematically.
Results: Clinicians’ beliefs about molecular tests could be grouped into two categories: perceived potential of 
molecular diagnostics to improve antibiotic prescribing (Molecular Diagnostic Necessity) and concerns about how 
the test results could be implemented into practice (Molecular Diagnostic Concerns). Molecular Diagnostic Necessity 
stemmed from beliefs that positive results would facilitate targeted antimicrobial therapy; that negative results would 
signal the absence of a pathogen, and consequently that having the molecular diagnostic results would bolster 
clinicians’ prescribing confidence. Molecular Diagnostic Concerns included unfamiliarity with the device’s capabili-
ties, worry that it would detect non-pathogenic bacteria, uncertainty whether it would fail to detect pathogens, and 
discomfort with withholding antibiotics until receiving molecular test results.
Conclusions: Clinicians believed rapid molecular diagnostics for pneumonias were potentially important and were 
open to using them; however, they harboured concerns about the tests’ capabilities and integration into clinical 
practice. Implementation strategies should bolster users’ necessity beliefs while reducing their concerns; this can be 
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Background
Rapid molecular diagnostic tests for pneumonia patho-
gens may improve antimicrobial stewardship (AMS). 
Results become available within 1 to 6 h, with accurate 
detection of multiple respiratory bacteria, viruses, and 
antimicrobial resistance genes directly from respiratory 
secretions without culture [1]. Commercially available 
rapid tests for pneumonia presently comprise the BioFire 
FilmArray Pneumonia panel (bioMérieux), the Unyvero 
Hospitalised Pneumonia panel (Curetis) and the FTD 
Respiratory Pathogens 33 (Fast Track Diagnostics) [1]. 
Other tests are in development.
Such tests may be particularly useful in intensive care 
units (ICUs), where patients with pneumonia are fre-
quent [2, 3], there is an increase the risk of rapid dete-
rioration and death [3, 4], and thus there is a demand 
for urgent antimicrobial treatment [5, 6]. Recommended 
practice for a suspected pneumonia include the prescrip-
tion of empiric broad-spectrum antibiotics, with refine-
ment once results of laboratory cultures become available 
(typically after 48–72 h) [5]. This approach is improvable 
because: (a) unnecessary antibiotics increase the risk of 
adverse consequences including direct toxicity, drug 
interactions, and Clostridium difficile infection [7], (b) 
empirical cover may prove ineffective for patients with 
drug resistant organisms [8], and (c) liberal broad-spec-
trum use drives antimicrobial resistance (AMR).
Molecular diagnostics can identify pathogens and 
their resistance genes within hours rather than days, 
potentially directing early tailored antimicrobial ther-
apy [9]. Randomised-control trials (RCTs) are com-
paring outcomes and AMS in molecular diagnostic 
and conventional microbiology-guided antimicrobial 
treatment for pneumonias [1]. For example, INHALE 
(ISRCTN16483855) has implemented the evaluation of 
point-of-care molecular tests for pneumonias in 12 UK 
ICUs [10].
Clinicians’ endorsement and uptake of molecular tests 
is crucial to maximise engagement in the context of such 
a RCT and for any subsequent deployment. Yet, adoption 
may be impeded if users harbour unaddressed concerns 
or if device usage is incompatible with local practice [11]. 
For instance, a recent RCT found that a highly sensitive 
rule-out test did not improve AMS for ICU patients with 
suspected VAP, likely due to incongruity with local pre-
scribing culture [12].
Clinicians’ beliefs about molecular diagnostics remain 
largely unknown, with the UK Department of Health and 
Social Care identifying a lack of understanding front-
line needs as a potential delayer to the clinical adoption 
of molecular tests [13]. Accordingly, we explored inten-
sivists’ beliefs of molecular diagnostics before the tests’ 
implementation for the INHALE RCT.
Methods
This study is reported following Standards for Report-
ing Qualitative Research guidelines [14]. It employed 
vignette-based interviews (VBIs) using an interpretivist 
approach to understand clinicians’ beliefs of molecular 
diagnostics as a decision aid. The data are derived from 
the same interview transcripts as Pandolfo and col-
leagues [15], but were analysed separately and meet Fine 
and Kurdek’s criteria for publishing multiple reports 
from one dataset [16].
Setting
Interviews occurred in four UK ICUs that varied in 
patient population and prevalence of multi-drug resist-
ant organisms. One was a large district general hospital 
in Norfolk; the remainder were London-based and com-
prised a tertiary referral hospital, a paediatric hospital, 
and a private hospital with an international patient popu-
lation. None had molecular diagnostic tests for pneumo-
nia available at the time of this research.
Inclusion criteria
All intensivists practicing at the four participating ICUs 
were eligible to participate. Clinicians who could spare 
time from clinical duties were recruited via local promo-
tion after ward rounds.
This research received Health Research Authority 
approval before data collection; all participants gave writ-
ten informed consent.
Vignette‑based interview methodology
Semi-structured VBIs explored clinicians’ antibiotic 
decision-making processes. Participants read a vignette 
depicting a hypothetical patient exhibiting signs of pneu-
monia (see Additional file  1 for vignette and interview 
guide). They then applied their expertise to determine 
whether to wait or to start antimicrobial treatment. We 
explored the perceived utility of molecular test results for 
accomplished by publicising the tests’ purpose and benefits, identifying and addressing clinicians’ misconceptions, 
establishing a trial period for first-hand familiarisation, and emphasising that, with a swift (e.g., 60–90 min) test, antibi-
otics can be started and refined after molecular diagnostic results become available.
Keywords: Rapid molecular diagnostics, Antimicrobial prescription, Intensive care
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this patient, followed by further detailed discussions of 
issues raised. Since participants may not have been famil-
iar with specific devices, interviews asked generally about 
molecular tests for pneumonia. We posited a notional 
six-hour result turnaround time because this is achiev-
able with two devices considered for the INHALE RCT. 
The vignette was pilot-tested with five non-participating 
ICU consultants and had no ‘correct’ answers because its 
purpose was to encourage reflection on decision-making 
processes.
Interviews were audio-recorded and conducted face-
to-face in each site’s ICU by NB and YJ. Both have clini-
cal pharmacy backgrounds, with qualitative research and 
interviewing experience.
Analysis
Interviews were anonymised, professionally transcribed, 
and entered into NVivo V.12. AMP (a research psycholo-
gist), NB, and YJ verified transcription accuracy. Data 
were analysed by AMP and NB using thematic analysis, 
following Braun and Clarke’s recommendations [17].
We adopted an inductive approach whereby data were 
coded to capture themes that represented a pattern of 
responses across transcripts. Themes were then deduc-
tively mapped onto the Necessity-Concerns Framework 
(NCF). NCF proposes that patients’ adherence to rec-
ommended treatment plans is influenced by their beliefs 
about the importance of their treatment and their treat-
ment concerns [18]. Consistent with Pandolfo and col-
leagues [15], we adapted the principles of NCF to explore 
intensivists’ beliefs regarding molecular diagnostics as 
a decision aid for their patients’ treatments. ‘Molecu-
lar Diagnostic Necessity’ refers to clinicians’ perceived 
importance of molecular diagnostic results in practice 
while ‘Molecular Diagnostic Concerns’ are their beliefs 
about the consequences associated with test adoption 
[19].
Results
Interviews occurred between August and December 
2018, were between seven and 20  min in length, and 
enrolment continued until data saturation [20]. Total 
audio-recording duration was approximately 4.5 h.
Participants comprised seven early-career trainees, 
sixteen middle-grade trainees, and eleven consultants. 
Eleven participants were employed at Hospital 1, ten at 
Hospital 2, seven at Hospital 3, and six at Hospital 4. All 
intensivists practicing at Hospital 2 treated children and 
neonates; remaining participants treated adult patients. 
Interviews were individual except in one case where one 
early-career trainee and one middle-grade trainee were 
interviewed together.
We describe clinicians’ perceived importance of molec-
ular diagnostics followed by their concerns. Tables  1 
and 2 show sub-themes and supporting quotations for 
Molecular Diagnostic Necessity and Molecular Diagnos-
tic Concerns themes, respectively. There were no notable 
differences between paediatric- and adult-treating doc-
tors’ beliefs.
Molecular Diagnostic Necessity: molecular diagnostic 
results improve antibiotic prescription practices
Positive results facilitate choosing targeted antibiotics
Positive molecular diagnostic results (i.e., detection of 
bacterial pathogen by the test) were generally believed 
to facilitate antibiotic choice by rapidly identifying the 
organism(s) and predicting their antibiotic susceptibili-
ties (Quotes 1–3). Currently, this information would be 
available approximately 72 h after the initial prescribing 
decision, leading to lengthy courses of potentially sub-
optimal therapy. Many participants felt that molecular 
test results would encourage either starting appropriate 
antibiotics at the outset or swiftly de-escalating empirical 
therapy to narrow-spectrum antibiotics.
Positive results lower threshold for starting antibiotics
In addition to improving antibiotic choice, ten clinicians 
asserted that positive results would lower their thresh-
old for starting antibiotics. For example, one trainee lik-
ened molecular diagnostics to other infection indicators 
(e.g., white cell count in blood) which give “proof” of an 
infection but should be combined with the clinical con-
text before making an antimicrobial decision (Quote 4). 
This decision was frequently described as reflecting a 
combination of clinical factors, including prospectively, 
the molecular test result. None of our participants said 
that they would start antibiotics solely based on positive 
results (Quote 5).
Some doctors stated that molecular diagnostics would 
not influence their threshold to start antimicrobial ther-
apy (Quote 6). These clinicians believed that they would 
exclusively use this test to choose appropriate antibiotics 
because their decision to start antibiotics would only be 
based on the clinical context (Quote 7).
Negative results indicate absence of respiratory infection
Negative results (i.e., no detection of bacteria or resist-
ance genes) would generally be interpreted to indicate 
that a respiratory infection was unlikely. Some clinicians 
believed that a negative result in a clinically stable patient 
would encourage withholding or stopping antibiotics 
(Quotes 8–9), whereas a negative result in a deteriorat-
ing patient would be interpreted to indicate a non-respir-
atory source of infection (Quote 9).
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Molecular diagnostic results increase confidence 
in prescribing decisions
When currently making antibiotic decisions, some par-
ticipants reported experiencing negative emotions like 
“angst” and “panic” (Quotes 10–11). They described 
uncertainty regarding whether their prescribing was 
appropriate and worried that it contributed to AMR 
(Quotes 10–11). This reflects the present difficulty of 
verifying the appropriateness of antibiotic decisions until 
laboratory culture results become available.
Such participants believed that the information pro-
vided by the molecular test would make them “happier” 
and more “confident” in their prescribing (Quotes 10–11). 
They believed that their prescribing decisions would be 
Table 1 Supporting quotations for Molecular Diagnostic Necessity theme
CRP C-reactive protein, PCR polymerase chain reaction
Subtheme Supporting quotations
Positive results facilitate choosing targeted antibiotics 1. [Molecular diagnostics] would provide something more diagnostic than just a non-specific 
CRP or white cells that could guide specific antibiotic choice if we wanted to start them. 
Because, of course, in most cases, we just have to choose the most appropriate antibiotic 
based on what we think is the cause, which, depending on how concerned we are about 
the patient, it would be… the more concerned you are about them, or the more unwell 
they look, the broader-spectrum antibiotic you might choose. So, it could be helpful to 
perhaps not just start them on meropenem or Tazocin [Piperacillin/Tazobactam]. –P15, 
middle-grade trainee, Hospital 3
2. […] if you had something [i.e., molecular diagnostics] that could give you quicker results 
you could give someone more appropriate antibiotics from the start. –P20, early-career 
trainee, Hospital 4
3. [Molecular diagnostics] would mean your rationalisation of your antibiotic regime would 
be much faster. You’d be able to switch to one with the correct sensitivities within six hours 
rather than 12 to 24, which would be much better. –P21, middle-grade trainee, Hospital 3
Positive results lower threshold for starting antibiotics 4. […] if I had proof that there was a bacteria [sic] in someone who was spiking a tempera-
ture, then I think I would be more likely to start antibiotics. […] In the same way if I had a 
positive urine dip or a consolidation on a chest X-ray. –P44, middle-grade trainee, Hospital 1
5. […] even if there is a positive result in the test I would still think about starting it [antibiot-
ics]. I wouldn’t start it automatically. –P8, consultant, Hospital 4
6. [Molecular diagnostics] might change what [antibiotic] I give but it wouldn’t decide 
whether I give anything. –P29, consultant, Hospital 4
7. For starting antibiotics, it would probably not be helpful to know the microbiology [i.e., 
molecular diagnostic results] as such. Because for starting antibiotics, or for a decision 
of which antibiotics, you need to have a context. Once you know that the patient is 
deteriorating in some way, and the context is triggering the confirmation that this is not 
inflammation, it is actually infection, obviously, to know what is going on in the body, with 
a name with a species, can make a huge difference, definitely. –P1, consultant, Hospital 3
Negative results indicate absence of respiratory infection 8. […] if that [molecular test result] was negative, I wouldn’t give her [vignette patient] any 
antibiotics. –P35, senior trainee, Hospital 2
9. If that [molecular test] comes up negative and I’ve got a patient who, yes, at the moment 
doesn’t look particularly infected, probably just still sit, watch and wait and see. […] But, a 
clear negative in a patient who’s otherwise now looking to be frankly septic, more septic 
than this does, then it might change the spectrum antibiotics I want to consider. So, say 
that [central] line was relatively new, so maybe I’m more suspicious of the line than I would 
have been otherwise. […] where it’s clearly negative, then it would change my thinking 
around other likely sources of infection. –P48, consultant, Hospital 1
Molecular diagnostic results increase confidence in 
prescribing decisions
10. [Having molecular test results] would mean that you can be confident that you’ve identi-
fied a pathogen that is sensitive, and that you could use a more narrow-spectrum antibi-
otic to focus that pathogen that you think is responsible for the sepsis, rather than having 
a bit of a panic using a broad-spectrum antibiotic. […] [Molecular results will] help a lot in 
terms of keeping the more powerful antibiotics for the situations in which you really need 
them. And that, in turn, will help to reduce the antibiotic resistance in the future. –P53, 
middle-grade trainee, Hospital 3
11. […] [If the molecular test] comes back positive, I come out of this state of diagnostic 
uncertainty, I feel much happier now. Because while I’m in the waiting zone I’m in a state of 
angst, have I made the right decision, have I made the wrong decision? […] And so great, 
if I’ve made a diagnosis more quickly, it’s lovely that we remove the diagnostic angst. And 
I can be happy that I’m now making a good decision for the patient and by proxy a good 
decision for the population. I don’t have to feel bad about needlessly increasing antibiotic 
resistance. –P43, consultant, Hospital 1
Page 5 of 8Pandolfo et al. Antimicrob Resist Infect Control           (2021) 10:95  
Table 2 Supporting quotations for Molecular Diagnostic Concerns theme
PCR polymerase chain reaction
a This is a misapprehension; the device does not ‘grow’
Subtheme Supporting quotations
Unfamiliarity with molecular diagnostic test capabilities 12. I need to know about the device, I think. What can it detect, in what 
populations has it been used, how confident can I be? We all know that 
I’ve got a fairly poor set of clinical tools for defining respiratory infection 
at the moment. But it’s before I’m going to start interpreting another one 
I need to know a bit more about that. –P48, consultant, Hospital 1
13. I’m not familiar with this machine; I’ve survived 30 years without having 
one. […] because I just don’t have a feel for the machine, I’d have to 
try it out for a bit and see what the results are. We have to try and use 
evidence based, don’t we? I’d be reassured if I knew that either it worked 
really, really well or, on the other hand, that it didn’t. –P36, consultant, 
Hospital 2
14. Products come in and tests come in and it doesn’t necessarily change 
what we’re actually doing on a day to day until we’ve seen it work a few 
times. –P58, middle-grade trainee, Hospital 1
Molecular diagnostics detecting non-pathogenic bacteria may lead to 
over-treatment
15. […] how convinced would I be that it’s [molecular test] picking up a 
pathogen rather than just an incidental coloniser. I’m not sure it would 
change what I’d do. –P6, consultant, Hospital 3
16. […] there’s no test which is 100% specific, and there’s no test which is 
100% sensitive. So yes, I’m thinking whether this [test] would lead to over-
prescribing of antibiotics that might lead to an increase in drug resistance 
[…] That’s why it’s very important to know how sensitive and specific 
the PCR is. There are a lot of commensals in our respiratory tract. –P31, 
middle-grade trainee, Hospital 2
17. […] whether that [positive result] is a colonisation rather than infection 
it would still be the same decision-making processes. So new tempera-
ture, a change in the inflammatory markers, a change in the secretion 
burden. –P45, consultant, Hospital 1
Molecular diagnostics failing to detect pathogens may lead to under-
treatment
18. […] if I’ve  growna nothing I’m not sure whether that would be depend-
ing on the sensitivities or whether that’d be reassuring enough to not 
cover the chest and just cover the abdomen. –P58, middle-grade trainee, 
Hospital 1
19. If she [vignette patient] didn’t bring up anything [i.e., negative result], 
but we still suspected a chest infection, or the X-ray showed something, 
then we would start [antibiotics]. –P2, early-career trainee, Hospital 4
Concern of patient deterioration while awaiting molecular diagnostic 
results
20. […] six hours doesn’t seem that long. But that could have a detrimental 
effect because six hours could be too long for this patient. –P24, early-
career trainee, Hospital 1
21. If I thought it [molecular results] was something that was very convinc-
ing and she [vignette patient] was quite stable and I could wait two 
hours, then yes, potentially. But it doesn’t sound like you’re portraying a 
stable case; you’re portraying someone that has come from a local unit 
looking like a bronchiolitis, getting worse, needing intubating. –P54, 
middle-grade trainee, Hospital 2
22. I don’t think you could justify waiting six hours to treat someone if 
they’ve got overt signs of sepsis. –P21, middle-grade trainee, Hospital 3
23. I wouldn’t start [antibiotics], I would wait a few hours because if I know 
in a couple of hours I’d have a result and she’s [vignette patient] not in 
shock and not very bad I would wait to see if something comes up posi-
tive. –P23, middle-grade trainee, Hospital 2
24. Because if you knew what the answer would be within six hours, and 
given that she’s [vignette patient] not systemically unwell at the moment, 
I would be more comfortable holding off [antibiotics]. –P47, early-career 
trainee, Hospital 4
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beneficial to their patient and society and felt that access 
to these tests would encourage AMS practices.
Molecular Diagnostic Concerns: integrating molecular 
diagnostics into practice
Unfamiliarity with molecular diagnostic test capabilities
Many clinicians stated that they needed to familiar-
ise themselves with the molecular test before using its 
results in practice. First, they wanted more information 
about the test, including its sensitivity, specificity, and 
its place in the diagnostic process (Quote 12). Several 
raised misconceptions about the test’s capabilities (e.g., it 
would prove the absence of all possible resistance genes 
and mutations; Quote 10). Second, they wanted first-
hand experience to verify the test’s suitability (Quote 
13). These participants felt a sense of caveat emptor—as 
future users of the test’s results, these clinicians believed 
that familiarisation was essential to understand the test’s 
capabilities and to make an informed decision about its 
usefulness in practice (Quotes 13–14). These participants 
would not adopt the test if, after familiarisation, they 
concluded that it did not meet their standards or would 
negatively impact patient care.
Molecular diagnostics detecting non‑pathogenic bacteria 
may lead to over‑treatment
Concerns were common that the molecular test would 
detect organisms present, but of no consequence to the 
patient (Quote 15). Many clinicians worried that the test 
would detect non-pathogenic bacteria, and that, para-
doxically, this might encourage unnecessary antibiotic 
prescriptions (Quote 16). To mitigate against antibi-
otic over-treatment based on detection of colonisation 
rather than infection, some participants stressed that 
they would not automatically prescribe based on the test 
result. They would combine the results with the clini-
cal context to determine the likelihood that the bacteria 
detected were causing current disease before making a 
decision (Quote 17).
Molecular diagnostics failing to detect pathogens may lead 
to under‑treatment
Some clinicians reported that negative results would not 
be reassuring enough to withhold or stop antibiotics. 
These doctors were uncertain whether the test was able 
to detect all possible respiratory pathogens (Quote 18). 
They consequently believed that negative results should 
be overridden by other evidence of respiratory infection 
(e.g., chest X-ray consolidation), which would lead them 
to prescribe or continue antibiotics (Quote 19).
Concern of patient deterioration while awaiting molecular 
diagnostic results
Many early-career and middle-grade trainees assumed 
that they would need to withhold antibiotics until molec-
ular test results become available; no consultants took 
this view. Consequently, some junior doctors expressed 
discomfort with the prospect of withholding antibiot-
ics for up to 6 h. They worried that both the vignette 
and their actual patients would significantly deteriorate 
within this period (Quotes 20–21), believing that with-
holding antibiotics would be indefensible if the patient 
was exhibiting signs of sepsis (Quote 22).
Other trainees felt more comfortable with withholding 
antibiotics until receiving molecular test results. These 
participants believed that the patient was stable enough 
to ‘wait and watch’ and valued using the results to aid 
their ultimate prescription decision (Quotes 23–24).
Discussion
This is the first study exploring UK intensivists’ sali-
ent beliefs influencing molecular diagnostic test uptake. 
Consistent with the NCF, facilitators related to clinicians’ 
beliefs that molecular tests would improve AMS whereas 
barriers related to their concerns about integrating these 
tests into clinical practice [19].
Many participants were open to using the molecular 
test because they believed that its results would improve 
antibiotic prescription practices. They saw positive test 
results, with early specific identification of a pathogen, 
as facilitating targeted antimicrobial therapy. Similarly, 
they viewed negative results to signal the likely absence 
of respiratory infection and thought that these results 
would provide reassurance that withholding an antibiotic 
prescription was appropriate. Our findings are consist-
ent with arguments that molecular diagnostics would aid 
the optimisation of antimicrobial therapy [1, 9], and that 
it could balance the competing priorities of individual 
patients with AMR [21, 22].
Despite clinicians recognising the potential of molecu-
lar tests, concerns about tests’ integration into clinical 
practice may impede uptake. Consistent with previous 
assertions [1, 21], participants worried that a molecular 
test’s high sensitivity would lead to reporting of colonis-
ing bacteria, which, paradoxically, could prompt unnec-
essary antimicrobial therapy. They also raised concerns 
about unfamiliarity with the test, misapprehensions 
about its capabilities, uncertainty whether it would fail to 
detect pathogens, and worry about withholding antibiot-
ics until receiving test results. Clinicians may also hold 
these beliefs regarding the ability of conventional micro-
biology to find organisms, especially when antibiotics 
have been deployed [23].
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Individual and environmental factors may also influ-
ence prescribers’ acceptance of molecular diagnostics. 
Individual clinicians’ trust in molecular diagnostics may 
affect its usage; for example, prescribers with low levels 
of trust in the machine likely would harbour concerns 
while having low beliefs about the device’s utility. Simi-
larly, the prescribing environment may affect machine 
uptake. For instance, unit-specific norms may encourage 
continuing empiric antibiotics for a minimum course; as 
such, receiving rapid test results may not impact antibi-
otic de-escalation or stopping. Thought should also be 
given to machine placement, whether at the point-of-care 
or in the laboratory.
Our findings show the importance of understanding 
clinicians’ beliefs about molecular diagnostic tests to 
ensure that they understand their rationale, and to suf-
ficiently address their concerns. To encourage molecular 
diagnostic uptake in ICU—whether for RCTs or for per-
manent use—implementation strategies should bolster 
users’ necessity beliefs while reducing concerns; this may 
be achieved with relatively simple solutions (summarised 
in Table 3).
This study has limitations. Firstly, our interviews were 
conducted before the molecular diagnostic test was 
deployed for the INHALE trial. Different beliefs may 
emerge after implementation and should be explored. 
Secondly, we interviewed ICU intensivists as the INHALE 
RCT runs with the molecular test located in ICUs; how-
ever some clinicians have recommended collaborating 
with microbiologists during test implementation [21, 
24]. Future research will investigate ICU microbiolo-
gists’ beliefs of molecular diagnostics to understand their 
barriers and facilitators to adoption. The INHALE team 
has also collaborated with unit microbiologists to create 
site-specific prescribing algorithms that aid translation of 
machine output to prescribing advice. Thirdly, clinicians’ 
beliefs may differ for non-respiratory molecular tests and 
should be examined in future research. Lastly, while we 
have endeavoured to sample from diverse hospitals, we 
recognise that clinicians’ beliefs may vary elsewhere in 
the UK and in other countries.
Conclusions
This study is the first to characterise prescribers’ beliefs 
about molecular diagnostics as facilitators and barri-
ers to applying it to antibiotic prescribing for patients 
with suspected pneumonia. Our findings demonstrate 
the importance of prescribers’ beliefs as determinants 
of molecular diagnostic uptake. If this technology 
proves successful in improving antibiotic prescribing 
and stewardship, interventions should understand and 
address these beliefs to ensure the optimal application 
of molecular diagnostics in clinical practice.
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Establish a trial period for clinician first-hand familiarisation
Withholding antibiotics until receiving 
molecular diagnostic results
Emphasise that empiric antibiotics can be started and refined after molecular diagnostic results become 
available
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